MedTrace Logo

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

NCT00398528 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2007-12-05

No results posted yet for this study

Summary

Impaired short term memory, attention and concentration lapses, and slower processing of information occur in up to 40-65% of patients with Multiple Sclerosis (MS). The quality of life of individuals with MS is impacted to the degree with which they experience these symptoms.

There are several medications approved by the United States Food and Drug Administration (FDA) to treat MS symptoms and to modify (slow) disease course. Traditional approaches to determining the effectiveness of medications used in treating MS rely on reports of the number of relapses an individual experiences, as well as standard clinical tests, such as the Kurtzke Expanded Disability Status Scale (EDSS).

This research study will look at whether the functional magnetic resonance imaging (fMRI) scan can be used as a tool for measuring changes in the brain associated with treatment in MS patients. Unlike a typical MRI which provides structural information about the brain, the fMRI provides information about brain activity during performance of cognitive or motor tasks.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG

Glatiramer acetate, (Copaxone®)

DRUG

IFN-β-1a, (Avonex®)

Sponsors & Collaborators

  • Neurognostics

    lead INDUSTRY

Principal Investigators

  • Catherine L Elsinger, PhD · Neurognostics, Inc.

  • Stephen M Rao, PhD · Neurognostics, Inc.

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00398528 on ClinicalTrials.gov